Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SVRA
stocks logo

SVRA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.117
-10.25%
--
--
-0.120
-0%
--
--
-0.122
-12.5%
Estimates Revision
The market is revising No Change the revenue expectations for Savara Inc. (SVRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 71.24%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.11%
In Past 3 Month
Stock Price
Go Up
up Image
+71.24%
In Past 3 Month
Wall Street analysts forecast SVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SVRA is 10.43 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast SVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SVRA is 10.43 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.370
sliders
Low
7.00
Averages
10.43
High
16.00
Current: 6.370
sliders
Low
7.00
Averages
10.43
High
16.00
Oppenheimer
Oppenheimer
Outperform
maintain
$8 -> $9
2025-11-14
Reason
Oppenheimer
Oppenheimer
Price Target
$8 -> $9
2025-11-14
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Savara to $9 from $8 and keeps an Outperform rating on the shares. Ahead of December 2025 BLA submission for MOLBREEVI, the firm continues to see a more than $1B opportunity for MOLBREEVI in aPAP following recent updated claims data giving line of sight to at least 1,000 patients by launch with 750 already identified.
Citizens JMP
Jonathan Wolleben
Outperform
to
Outperform
downgrade
$11 -> $10
2025-11-13
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$11 -> $10
2025-11-13
downgrade
Outperform
to
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Savara to $10 from $11 and keeps an Outperform rating on the shares. Savara remains on track to resubmit its biologics license application for Molbreevi in December, with an MAA submission in the EU and UK expected in 1Q26, the analyst tells investors in a research note. The firm is impressed with management's execution on quickly resolving manufacturing deficiencies that prompted a complete response letter in May.
Citizens JMP
Outperform
maintain
$8 -> $11
2025-10-23
Reason
Citizens JMP
Price Target
$8 -> $11
2025-10-23
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Savara to $11 from $8 and keeps an Outperform rating on the shares. The firm's pulmonologist survey indicates high demand for Molbreevi. 60% of those surveyed want to use Molbreevi, which should translate to blockbuster sales, the analyst tells investors in a research note. Citizens says Savara remains on track to resubmit its application for Molbreevi in December.
LifeSci Capital
Francois Brisebois
Outperform
initiated
$11
2025-10-14
Reason
LifeSci Capital
Francois Brisebois
Price Target
$11
2025-10-14
initiated
Outperform
Reason
LifeSci Capital analyst Francois Brisebois initiated coverage of Savara with an Outperform rating and $11 price target.
Guggenheim
Buy
maintain
$8 -> $11
2025-09-09
Reason
Guggenheim
Price Target
$8 -> $11
2025-09-09
maintain
Buy
Reason
Guggenheim raised the firm's price target on Savara to $11 from $8 and keeps a Buy rating on the shares following what the firm calls "a series of positive updates from the company" over the past several weeks. Following these updates, the firm now estimates peak probability-adjusted annual U.S. Molbreevi sales of $962M, up from a prior view of $680M, the analyst tells investors.
Oppenheimer
Oppenheimer
Outperform
maintain
$6 -> $8
2025-09-08
Reason
Oppenheimer
Oppenheimer
Price Target
$6 -> $8
2025-09-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Savara to $8 from $6 and keeps an Outperform rating on the shares following updated analysis pointing to 5,500 aPAP patients in the U.S. from previous estimates of 3,600 in 2023. This refreshed analysis of claims data giveline of sight to at least 1,000 patients by launch with 750 patients already identified. With no approved therapies in the U.S. to treat aPAP, these claims data reinforce the unmet need ahead of MOLBREEVI BLA submission in December, the firm says. With the analytical package being finalized and the recent NEJM publication underscoring the MOLBREEVI's ability to address the underlying pathophysiology of aPAP, Oppenheimer is increasingly confident in a potential August 2026 approval, if granted Priority Review.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Savara Inc (SVRA.O) is -15.11, compared to its 5-year average forward P/E of -6.92. For a more detailed relative valuation and DCF analysis to assess Savara Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.92
Current PE
-15.11
Overvalued PE
-4.03
Undervalued PE
-9.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.38
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.12
Undervalued EV/EBITDA
-4.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.28
Current PS
0.00
Overvalued PS
88.41
Undervalued PS
-59.85
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 373.33% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 373.33% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SVRA News & Events

Events Timeline

(ET)
2025-12-02
14:30:00
Savara Shares Drop 2% to $5.73 Amid M&A Rumors
select
2025-12-02
08:41:00
Savara and Pari Jointly Obtain Patent for Molbreevi Delivery System
select
2025-11-12 (ET)
2025-11-12
16:13:35
Savara Announces Q3 Earnings Per Share of 14 Cents, Exceeding Consensus Estimate of 13 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Yahoo Finance
PinnedSavara and PARI Awarded European Patent for Drug-Device Combination

  • Patent Issuance: Savara (SVRA) announced that the European Patent Office has granted a patent for a "Drug-Device Combination."

  • Significance: This patent could enhance Savara's position in the market by protecting its innovative drug delivery technology.

[object Object]
Preview
8.5
12-02SeekingAlpha
PinnedSavara Inc. Rises in Value Amid Acquisition Rumors

  • Takeover Speculation: Savara Inc. (SVRA) experienced a slight increase of 0.2% amid rumors of potential takeover interest, although the identity of the buyer remains unknown.

  • Stock Performance: The company's shares have surged over 80% this year, contributing to a market capitalization of $1.4 billion.

[object Object]
Preview
2.0
11-29Benzinga
Major Stocks Including Micron, Endeavour Silver, First Majestic Silver, and Applied Digital Experience Gains on Friday

  • U.S. Stock Market Performance: U.S. stocks rose on Friday, with the Dow Jones gaining approximately 300 points, driven by positive earnings reports, particularly from Dell, which boosted investor sentiment in the tech sector.

  • Micron Technology Surge: Shares of Micron Technology increased by 2.5% to $235.92, as investors interpreted Dell's strong earnings as a sign of broader strength in the technology market.

  • Notable Stock Gains: Several companies saw significant stock price increases, including DeFi Technologies (up 20.5%), YD Bio Ltd (up 13.7%), and Savara Inc (up 12.3%), reflecting positive developments in their respective sectors.

  • Precious Metals and Crypto Stocks Rise: Stocks related to precious metals and cryptocurrencies also experienced gains, with First Majestic Silver Corp and Intel Corporation rising notably, as gold and silver prices increased and Bitcoin surpassed $90,000.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Savara Inc (SVRA) stock price today?

The current price of SVRA is 6.37 USD — it has increased 1.11 % in the last trading day.

arrow icon

What is Savara Inc (SVRA)'s business?

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

arrow icon

What is the price predicton of SVRA Stock?

Wall Street analysts forecast SVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SVRA is 10.43 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Savara Inc (SVRA)'s revenue for the last quarter?

Savara Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Savara Inc (SVRA)'s earnings per share (EPS) for the last quarter?

Savara Inc. EPS for the last quarter amounts to -0.14 USD, increased 27.27 % YoY.

arrow icon

What changes have occurred in the market's expectations for Savara Inc (SVRA)'s fundamentals?

The market is revising No Change the revenue expectations for Savara Inc. (SVRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 71.24%.
arrow icon

How many employees does Savara Inc (SVRA). have?

Savara Inc (SVRA) has 59 emplpoyees as of December 05 2025.

arrow icon

What is Savara Inc (SVRA) market cap?

Today SVRA has the market capitalization of 1.30B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free